Literature DB >> 2546824

Regulation of hepatic expression of IGF I and fetal IGF binding protein mRNA in streptozotocin-diabetic rats.

M Böni-Schnetzler1, K Binz, J L Mary, C Schmid, J Schwander, E R Froesch.   

Abstract

Hepatic mRNA levels of insulin-like growth factor I (IGF I) and of the fetal, nonglycosylated 32 kDa IGF-binding protein (BP) were analysed in diabetic, diabetic insulin- and IGF I-treated rats as well as in age-matched, healthy control animals. IGF ImRNA levels are reduced in diabetic rats and increased by insulin treatment. In contrast, the infusion of IGF I does not significantly upregulate IGF I mRNA levels. Fetal IGF BP mRNA expression is very low in healthy control animals, but high levels are found in diabetic rats. Insulin therapy lowers fetal IGF BP mRNA levels, whereas IGF I has no effect. We propose that insulin is a major regulator of the 32 kDa IGF BP levels in adult rats.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2546824     DOI： 10.1016/0014-5793(89)81465-6

Source DB:  PubMed          Journal:  FEBS Lett        ISSN： 0014-5793            Impact factor:   4.124


  11 in total

Review 1.  Somatomedin-1 (insulin-like growth factor-I) in clinical use. Facts and potential.

Authors:  Z Laron
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

2.  Polaprezinc exerts a salutary effect on impaired healing of acute gastric lesions in diabetic rats.

Authors:  R P Korolkiewicz; A Fujita; K Seto; K Suzuki; K Takeuchi
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

3.  Decrease in the glycosaminoglycan content in the skin of diabetic rats. The role of IGF-I, IGF-binding proteins and proteolytic activity.

Authors:  M Cechowska-Pasko; J Pałka; E Bańkowski
Journal:  Mol Cell Biochem       Date:  1996-01-12       Impact factor: 3.396

Review 4.  [Principles and clinical significance of insulin-like growth factors/somatomedins].

Authors:  E Weimann; W Kiess
Journal:  Klin Wochenschr       Date:  1990-10-17

5.  Regulation of binding proteins for insulin-like growth factors (IGF) in humans. Increased expression of IGF binding protein 2 during IGF I treatment of healthy adults and in patients with extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; C Schmid; H P Guler; M Waldvogel; C Hauri; E Futo; P Hossenlopp; M Binoux; E R Froesch
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor (IGF)-I and des(1-3)IGF-I.

Authors:  F M Tomas; S E Knowles; P C Owens; L C Read; C S Chandler; S E Gargosky; F J Ballard
Journal:  Biochem J       Date:  1991-06-01       Impact factor: 3.857

7.  Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.

Authors:  F M Tomas; S E Knowles; P C Owens; C S Chandler; G L Francis; F J Ballard
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

8.  Effect of insulin-like growth factor I infusion on renal hypertrophy in experimental diabetes mellitus in rats.

Authors:  A Flyvbjerg; K E Bornfeldt; H Orskov; H J Arnqvist
Journal:  Diabetologia       Date:  1991-10       Impact factor: 10.122

9.  Transient increase in renal insulin-like growth factor binding proteins during initial kidney hypertrophy in experimental diabetes in rats.

Authors:  A Flyvbjerg; U Kessler; B Dorka; B Funk; H Orskov; W Kiess
Journal:  Diabetologia       Date:  1992-06       Impact factor: 10.122

10.  A distal regulatory region of the insulin-like growth factor binding protein-2 (IGFBP-2) gene interacts with the basic helix-loop-helix transcription factor, AP-4.

Authors:  L Badinga; S Song; R C Simmen; F A Simmen
Journal:  Endocrine       Date:  1998-06       Impact factor: 3.925
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.